JP2005527602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527602A5 JP2005527602A5 JP2004501406A JP2004501406A JP2005527602A5 JP 2005527602 A5 JP2005527602 A5 JP 2005527602A5 JP 2004501406 A JP2004501406 A JP 2004501406A JP 2004501406 A JP2004501406 A JP 2004501406A JP 2005527602 A5 JP2005527602 A5 JP 2005527602A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- diazabicyclo
- propyl
- ene
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 racemates Chemical class 0.000 claims 79
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- GCJYLAWVUWEHLW-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]cyclopropanamine Chemical compound ClC1=CC=CC=C1CNC1CC1 GCJYLAWVUWEHLW-UHFFFAOYSA-N 0.000 claims 10
- IVEWTCACRDEAOB-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetic acid Chemical compound COC1=CC=CC=C1CC(O)=O IVEWTCACRDEAOB-UHFFFAOYSA-N 0.000 claims 9
- 230000000877 morphologic effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000002904 solvent Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 claims 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 5
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 230000036454 renin-angiotensin system Effects 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- LFGLSENCOIFTLS-MYQURODFSA-N (1r,5s)-n-[(2-chlorophenyl)methyl]-n-cyclopropyl-9-[(3s)-3-hydroxybutanoyl]-7-[4-[2-(2,3,6-trifluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide Chemical compound C=1([C@@]2([H])CNC[C@](N2C(=O)C[C@H](C)O)(CC=1C=1C=CC(CC(C)OC=2C(=C(F)C=CC=2F)F)=CC=1)[H])C(=O)N(C1CC1)CC1=CC=CC=C1Cl LFGLSENCOIFTLS-MYQURODFSA-N 0.000 claims 1
- HKXOGUWLPNRQOJ-UBLOXDIOSA-N (1s,5r)-n-[(2-chlorophenyl)methyl]-n-cyclopropyl-3-[(3r)-3-hydroxybutanoyl]-7-[4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide Chemical compound C=1([C@]2([H])CN(C[C@@](N2)(CC=1C=1C=CC(CCCOC=2C(=C(F)C=CC=2F)F)=CC=1)[H])C(=O)C[C@@H](C)O)C(=O)N(C1CC1)CC1=CC=CC=C1Cl HKXOGUWLPNRQOJ-UBLOXDIOSA-N 0.000 claims 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- CDDQBIWIOSSSDK-ORLCUPCUSA-N N[C@@H](CO)C(N1C[C@H](C(C(O)=O)=C(C2)C3=CC=C(CCCOC(C(F)=CC=C4F)=C4F)C=C3)N[C@H]2C1)=O.ClC1=C(CNC2CC2)C=CC=C1 Chemical compound N[C@@H](CO)C(N1C[C@H](C(C(O)=O)=C(C2)C3=CC=C(CCCOC(C(F)=CC=C4F)=C4F)C=C3)N[C@H]2C1)=O.ClC1=C(CNC2CC2)C=CC=C1 CDDQBIWIOSSSDK-ORLCUPCUSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 239000012050 conventional carrier Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- ILHIZUJWNGLALK-UHFFFAOYSA-N n-(2-phenylethyl)cyclopropanamine Chemical compound C1CC1NCCC1=CC=CC=C1 ILHIZUJWNGLALK-UHFFFAOYSA-N 0.000 claims 1
- KJYVKUQRRKDPAX-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]cyclopropanamine Chemical compound ClC1=CC=CC(CNC2CC2)=C1Cl KJYVKUQRRKDPAX-UHFFFAOYSA-N 0.000 claims 1
- QWMNTOVGKJAROU-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]ethanamine Chemical compound CCNCC1=CC=CC=C1Cl QWMNTOVGKJAROU-UHFFFAOYSA-N 0.000 claims 1
- UZYPFBRRGVZJNV-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]cyclopropanamine Chemical compound FC1=CC=CC=C1CNC1CC1 UZYPFBRRGVZJNV-UHFFFAOYSA-N 0.000 claims 1
- WYQUCNZBUBLJHN-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]cyclopropanamine Chemical compound CC1=CC=CC=C1CNC1CC1 WYQUCNZBUBLJHN-UHFFFAOYSA-N 0.000 claims 1
- BTBDLUOYLCXSMK-UHFFFAOYSA-N n-[(3,5-dimethoxyphenyl)methyl]cyclopropanamine Chemical compound COC1=CC(OC)=CC(CNC2CC2)=C1 BTBDLUOYLCXSMK-UHFFFAOYSA-N 0.000 claims 1
- NJHZDGHFBLATGX-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]cyclopropanamine Chemical compound ClC1=CC=CC=C1CCNC1CC1 NJHZDGHFBLATGX-UHFFFAOYSA-N 0.000 claims 1
- AOMAZSZEDRDSIF-UHFFFAOYSA-N n-[[3-(trifluoromethyl)phenyl]methyl]cyclopropanamine Chemical compound FC(F)(F)C1=CC=CC(CNC2CC2)=C1 AOMAZSZEDRDSIF-UHFFFAOYSA-N 0.000 claims 1
- USBAUXJPPHVCTF-UHFFFAOYSA-N n-benzylcyclopropanamine Chemical compound C=1C=CC=CC=1CNC1CC1 USBAUXJPPHVCTF-UHFFFAOYSA-N 0.000 claims 1
- 230000002988 nephrogenic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0204705 | 2002-04-29 | ||
| PCT/EP2003/003721 WO2003093267A1 (en) | 2002-04-29 | 2003-04-08 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005527602A JP2005527602A (ja) | 2005-09-15 |
| JP2005527602A5 true JP2005527602A5 (enExample) | 2006-06-01 |
| JP4041123B2 JP4041123B2 (ja) | 2008-01-30 |
Family
ID=29286070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501406A Expired - Fee Related JP4041123B2 (ja) | 2002-04-29 | 2003-04-08 | 新規なジアザビシクロノネン |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7427613B2 (enExample) |
| EP (1) | EP1501830B1 (enExample) |
| JP (1) | JP4041123B2 (enExample) |
| KR (1) | KR100783863B1 (enExample) |
| CN (1) | CN1649870A (enExample) |
| AT (1) | ATE527261T1 (enExample) |
| AU (1) | AU2003233963B2 (enExample) |
| BR (1) | BR0309498A (enExample) |
| CA (1) | CA2483241C (enExample) |
| CL (1) | CL2003002042A1 (enExample) |
| CO (1) | CO5631443A2 (enExample) |
| EC (1) | ECSP045378A (enExample) |
| ES (1) | ES2372931T3 (enExample) |
| HR (1) | HRP20041132A2 (enExample) |
| IL (1) | IL164767A0 (enExample) |
| IS (1) | IS7545A (enExample) |
| MA (1) | MA27305A1 (enExample) |
| MX (1) | MXPA04010608A (enExample) |
| NO (1) | NO20045042L (enExample) |
| NZ (1) | NZ536750A (enExample) |
| PL (1) | PL372141A1 (enExample) |
| RU (1) | RU2343153C2 (enExample) |
| TW (1) | TW200514786A (enExample) |
| UA (1) | UA80821C2 (enExample) |
| WO (1) | WO2003093267A1 (enExample) |
| ZA (1) | ZA200408283B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1780836A (zh) * | 2003-04-28 | 2006-05-31 | 埃科特莱茵药品有限公司 | 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物 |
| CN1780833A (zh) * | 2003-04-30 | 2006-05-31 | 埃科特莱茵药品有限公司 | 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用 |
| JP2006524654A (ja) * | 2003-04-30 | 2006-11-02 | アクテリオン ファマシューティカルズ リミテッド | 新規アザビシクロノネン誘導体 |
| CA2521938A1 (en) * | 2003-04-30 | 2004-11-11 | Actelion Pharmaceuticals Ltd | 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors |
| KR20060015573A (ko) * | 2003-05-02 | 2006-02-17 | 액테리온 파마슈티칼 리미티드 | 신규한 디아자비시클로노넨 유도체 |
| WO2004105762A1 (en) * | 2003-05-30 | 2004-12-09 | Actelion Pharmaceuticals Ltd | Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases |
| CN1863773A (zh) * | 2003-10-09 | 2006-11-15 | 埃科特莱茵药品有限公司 | 四氢吡啶衍生物 |
| JP2007508262A (ja) * | 2003-10-13 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規ジアザビシクロノネン誘導体およびその使用 |
| WO2005040173A1 (en) * | 2003-10-23 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| AU2004295092A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd. | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain |
| WO2005054243A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| WO2006021399A2 (en) * | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Azabicyclononene derivatives as renin inhibitors |
| JP2008510755A (ja) * | 2004-08-25 | 2008-04-10 | アクテリオン ファーマシューティカルズ リミテッド | ビシクロノネン誘導体 |
| WO2006021401A2 (en) * | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicylononene derivatives |
| WO2006021403A1 (en) * | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
| TW200634014A (en) * | 2004-12-08 | 2006-10-01 | Actelion Pharmaceuticals Ltd | Novel diazabicyclononene derivative |
| WO2006063610A1 (en) * | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
| GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| RU2007132438A (ru) * | 2005-01-28 | 2009-03-10 | Актелион Фармасьютикалз Лтд (Ch) | Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии |
| JP4297972B2 (ja) | 2005-05-27 | 2009-07-15 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピペリジンカルボン酸アミド誘導体 |
| GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| EP1968940B1 (en) | 2005-12-30 | 2014-04-02 | Novartis AG | 3 , 5-substitued piperidine compounds as renin inhibitors |
| AU2007210813A1 (en) * | 2006-02-02 | 2007-08-09 | Actelion Pharmaceuticals Ltd | Secondary amines as renin inhibitors |
| AU2007224368A1 (en) * | 2006-03-08 | 2007-09-13 | Actelion Pharmaceuticals Ltd | New amines |
| CA2688057A1 (en) | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd. | Novel case of renin inhibitors |
| NZ582098A (en) | 2007-06-25 | 2012-03-30 | Novartis Ag | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
| EP2190811B1 (en) | 2007-08-20 | 2013-08-07 | Merck Canada Inc. | Renin inhibitors |
| SG192543A1 (en) | 2008-05-05 | 2013-08-30 | Merck Canada Inc | 3, 4 - substituted piperidine derivatives as renin inhibitors |
| CN109721613B (zh) * | 2017-10-27 | 2021-07-30 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的大环酰胺化合物及其药物组合物和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3509161A (en) * | 1967-07-10 | 1970-04-28 | Boehringer & Soehne Gmbh | 3-phenyl-granatene-(2)-derivatives |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| US5268361A (en) * | 1991-06-07 | 1993-12-07 | Sri International | Hydroxyazido derivatives and related compounds as renin inhibitors |
| US5374719A (en) * | 1993-06-04 | 1994-12-20 | Eli Lilly And Company | Process for converting loracarbef dihydrate to loracarbef monohydrate |
| TR199800409T1 (xx) * | 1995-09-07 | 1998-05-21 | F.Hoffmann-La Roche Ag | Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler |
| EP0966464B1 (en) | 1997-03-03 | 2003-05-28 | Basilea Pharmaceutica AG | Substituted 2,4-diaminopyrimidines |
| US20060223795A1 (en) * | 2003-05-02 | 2006-10-05 | Oliver Bezencon | Novel diazabicyclononene derivatives |
| WO2005054243A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
-
2003
- 2003-04-08 WO PCT/EP2003/003721 patent/WO2003093267A1/en not_active Ceased
- 2003-04-08 NZ NZ536750A patent/NZ536750A/xx unknown
- 2003-04-08 MX MXPA04010608A patent/MXPA04010608A/es not_active Application Discontinuation
- 2003-04-08 BR BR0309498-7A patent/BR0309498A/pt not_active IP Right Cessation
- 2003-04-08 US US10/513,103 patent/US7427613B2/en not_active Expired - Fee Related
- 2003-04-08 IL IL16476703A patent/IL164767A0/xx unknown
- 2003-04-08 HR HR20041132A patent/HRP20041132A2/xx not_active Application Discontinuation
- 2003-04-08 RU RU2004134320/04A patent/RU2343153C2/ru not_active IP Right Cessation
- 2003-04-08 KR KR1020047016845A patent/KR100783863B1/ko not_active Expired - Fee Related
- 2003-04-08 JP JP2004501406A patent/JP4041123B2/ja not_active Expired - Fee Related
- 2003-04-08 CN CNA038097664A patent/CN1649870A/zh active Pending
- 2003-04-08 CA CA2483241A patent/CA2483241C/en not_active Expired - Fee Related
- 2003-04-08 AU AU2003233963A patent/AU2003233963B2/en not_active Ceased
- 2003-04-08 PL PL03372141A patent/PL372141A1/xx not_active Application Discontinuation
- 2003-04-08 EP EP03727287A patent/EP1501830B1/en not_active Expired - Lifetime
- 2003-04-08 ES ES03727287T patent/ES2372931T3/es not_active Expired - Lifetime
- 2003-04-08 AT AT03727287T patent/ATE527261T1/de not_active IP Right Cessation
- 2003-08-04 UA UA20041109469A patent/UA80821C2/uk unknown
- 2003-10-10 CL CL200302042A patent/CL2003002042A1/es unknown
- 2003-10-23 TW TW092129421A patent/TW200514786A/zh unknown
-
2004
- 2004-10-13 ZA ZA200408283A patent/ZA200408283B/xx unknown
- 2004-10-22 MA MA27914A patent/MA27305A1/fr unknown
- 2004-10-22 CO CO04106347A patent/CO5631443A2/es not_active Application Discontinuation
- 2004-10-22 EC EC2004005378A patent/ECSP045378A/es unknown
- 2004-11-19 NO NO20045042A patent/NO20045042L/no not_active Application Discontinuation
- 2004-11-22 IS IS7545A patent/IS7545A/is unknown
-
2008
- 2008-07-07 US US12/168,666 patent/US20080312242A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527602A5 (enExample) | ||
| CA2483241A1 (en) | Novel diazabicyclononene derivatives | |
| JP2005532371A5 (enExample) | ||
| JP2009533427A5 (enExample) | ||
| JP2010523674A5 (enExample) | ||
| RU2005102002A (ru) | Новые производные тетрагидропиридина | |
| US20110118292A1 (en) | Method of treating atherosclerosis, dyslipidemias and related conditions | |
| RU2007119307A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРИПИИ | |
| JP2011057693A5 (enExample) | ||
| JP2012505881A5 (enExample) | ||
| RU2009129119A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| JP2008500992A5 (enExample) | ||
| CA2683925A1 (en) | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors | |
| RU2012139828A (ru) | Производные пиразолопиперидина в качестве ингибиторов nadph-оксидазы | |
| JP2012525431A5 (enExample) | ||
| JP2008523041A5 (enExample) | ||
| JP2013519724A5 (enExample) | ||
| JP2012526082A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| JP2004526776A (ja) | 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| JP2018520151A (ja) | 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用 | |
| JP2008523102A5 (enExample) | ||
| EP2585069A1 (en) | Prokineticin 1 receptor antagonists for the treatment of pain | |
| RU2005137571A (ru) | Новые производные диазабициклононена | |
| JP2012517441A5 (enExample) |